Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor YH-53
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
Crystal structure of SAR-CoV-2 3CL protease complex with inhibitor YH-53
应用场景：
创建时间：
2023-11-29
相关数据集
Discovery of the Clinical Candidate S‑892216: A Second-Generation of SARS-CoV‑2 3CL Protease Inhibitor for Treating COVID-19
The coronavirus disease 2019 (COVID-19) pandemic crisis has been mitigated by worldwide efforts to develop vaccines and therapeutic drugs. However, there remains concern regarding public health and an
Figshare2025-07-05 更新30
Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 obtained in presence of 150 micromolar X77.
Crystal structure of the main protease (3CLpro/Mpro) of SARS-CoV-2 obtained in presence of 150 micromolar X77.
NIAID Data Ecosystem20
Global 3CL Protease Inhibitor Market Insights, Size, and Forecast By Application (Antiviral Therapy, Research and Development, Diagnostic Tools, Clinical Trials), By Drug Formulation (Oral, Injectable, Topical), By End Use (Hospitals, Clinics, Research Institutions, Pharmaceutical Companies), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Global 3CL Protease Inhibitor Market Insights, Size, and Forecast By Application (Antiviral Therapy, Research and Development, Diagnostic Tools, Clinical Trials), By Drug Formulation (Oral, Injectable
MAK Data Insights00
Table4_Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2.xlsx
Introduction: The pursuit of effective therapeutic solutions for SARS-CoV-2 infections and COVID-19 necessitates the repurposing of existing compounds. This study focuses on the detailed examination o
NIAID Data Ecosystem00
